Uncategorized
Shire alleges Allergan blocked Xiidra from Medicare contracts
Shire is alleging that Allergan has blocked Medicare Part D access to Xiidra in order to allow Restasis to keep a monopoly on dry eye treatments offered through Part D plans, according to a lawsuit filed in U.S. District Court, District of New Jersey.The suit claims Allergan has maintained a high market share by “employing egregiously anticompetitive and unlawful tactics.”